Patents Examined by Noble E Jarrell
  • Patent number: 10632099
    Abstract: This disclosure is directed to non-aromatic difluoro analogues of resorcylic acid lactones, pharmaceutical compositions comprising non-aromatic difluoro analogues of resorcylic acid lactones, and methods of treatment comprising non-aromatic difluoro analogues of resorcylic acid lactones.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: April 28, 2020
    Assignee: University of North Carolina at Greensboro
    Inventors: Mitchell P. Croatt, Lara Fakhouri, Nicholas H. Oberlies, Cedric Pearce
  • Patent number: 10633396
    Abstract: The present invention claims UV detectable (?>210 nm) potassium [18F]fluoride diaryl- and aryl-fused [2.2.2]cryptate complexes suitable for performing radio-labeling reactions to generate [18F] fluorinated species.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: April 28, 2020
    Inventors: Yousry M. A. Naguib, Ashraf Naguib, Ahmed Naguib
  • Patent number: 10633364
    Abstract: The invention relates to Crystal form I and Crystal form II of dihydrochloride of N-(4-((3-chloro-4-fluorophenyl)amino)-7-((7-methyl-7-azaspiro[3.5]nonan-2-yl)methoxy)quinazolin-6-yl)acrylamide represented by the following Formula (I), and preparation methods therefor, wherein the Crystal form I has an X-ray powder diffraction pattern having characteristic peaks at the 2? positions of 6.0±0.2°, 7.3±0.2°, 11.7±0.2°, 12.9±0.2°, 18.4±0.2°, 24.7±0.2°, and 26.3±0.2°, as determined by using Cu-K? radiation, and the Crystal form II has an X-ray powder diffraction pattern having characteristic peaks at the 2? positions of 5.0±0.2°, 7.0±0.2°, 10.1±0.2°, 17.0±0.2°, 26.0±0.2°, and 26.5±0.2°, as determined by using Cu-K? radiation.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: April 28, 2020
    Assignee: XUANZHU PHARMA CO., LTD.
    Inventors: Chutian Shu, Jinyuan Wang, Zhenhua Wang
  • Patent number: 10632127
    Abstract: The instant invention relates to novel conjugates of the compound of formula (I): S—L—A??(I) or salts thereof, wherein A is a ?-secretase inhibitor, L is a linker and S is a peptidase-specific substrate, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: April 28, 2020
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Johannes Aebi, Alexander Flohr, Juillerat-Jeanneret Lucienne, Golshayan Dela
  • Patent number: 10633360
    Abstract: The present invention relates to the synthesis of alkoxy substituted benzaldehydes obtained from the corresponding alkoxy substituted benzenes. Alkoxy substituted benzaldehydes are products of broad commercial interest and are used as end products and intermediates in flavor and fragrance applications and pharmaceutical ingredients. For example, 3,4-methylendioxy-benzaldehyde (also known as heliotropin or piperonal) is used widely both as a end product and intermediate for the above mentioned applications. Other examples include 3,4-dimethoxybenzaldehyde, 3,4,5-trimethoxybenzaldehyde and 3,4-ethylenedioxybenzene which are intermediates in the synthesis of active pharmaceutical intermediates.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: April 28, 2020
    Assignee: ANTHEA AROMATICS PRIVATE LIMITED
    Inventors: Manoj Kumar Mohapatra, Ramamohanrao Bendapudi, Paul Vincent Menacherry, Vincent Paul
  • Patent number: 10626099
    Abstract: The present disclosure provides processes for preparing (+)-pleuromutilin and synthetic (+)-pleuromutilin produced therefrom. Also provided are intermediates prepared thereby and processes for preparing these intermediates.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: April 21, 2020
    Assignee: California Institute of Technology
    Inventors: Elliot P. Farney, Sean S. Feng, Sarah Reisman
  • Patent number: 10626115
    Abstract: The present invention concerns novel fused pyrimidinone and triazinone derivatives containing bridged nitrogen, their process of preparation and their use as antifungal or antiparasitic agents.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: April 21, 2020
    Assignee: UNIVERSITE DE NANTES
    Inventors: Cédric Loge, Rémi Guillon, David Montoir, Fabrice Pagniez, Patrice Le Pape
  • Patent number: 10624343
    Abstract: A compound represented by formula (1) is described: The compound has an excellent efficacy for controlling plant diseases, and is thus useful as an active ingredient for an agent for controlling plant diseases.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: April 21, 2020
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Shinya Yamada
  • Patent number: 10604531
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: March 31, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Steven David Knight, Louis Vincent Lafrance, III, Xinrong Tian
  • Patent number: 10597402
    Abstract: Novel isohexide esters and isohexide compositions are prepared and used in improving skin health and condition.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: March 24, 2020
    Assignee: Sytheon Limited
    Inventor: Ratan K Chaudhuri
  • Patent number: 10597414
    Abstract: The present invention relates to a novel crystalline polymorphic form of 3-Hydroxy-4,5-bis-benzyloxy-6-benzyloxymethyl-2-phenyl-2-oxo-2?5-[1,2]oxaphosphinane and a method for preparing the same.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: March 24, 2020
    Assignee: PHOST'IN
    Inventors: Ludovic Clarion, Séverine Loiseau, Pierric Marchand, Morgan Pauchet
  • Patent number: 10577350
    Abstract: The present disclosure relates to a crystalline Forms A, B, and C of (R)—N-((4-methoxy-6-methyl-2-oxo-1,2-di-hydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide, each of which are useful as modulators the activity of histone methyl modifying enzymes. The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline forms and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: March 3, 2020
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, Alisha Arrigo, Donald Corson, Victor S. Gehling, Bruno Patrice Haché, Jean-Christophe Harmange, Jonathan Lane
  • Patent number: 10577383
    Abstract: The present invention provides compounds of Formula (I): wherein the substituents are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, and may be useful for for the treatment and/or prophylaxis of atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: March 3, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Joanne M. Smallheer, Ellen K. Kick, Meriah Neissel Valente, Carol Hui Hu, Oz Scott Halpern, Sutjano Jusuf
  • Patent number: 10576151
    Abstract: Modulation of glucose homeostasis by administration of ciclopirox (6-cyclohexyl-1-hydroxy-4-methylpyridin-2(1H)-one) is described. Methods can be utilized in treatment of conditions that involve loss of glucose homeostasis, such as diabetes, and in one particular embodiment type II diabetes. Ciclopirox is shown to stimulate p21 expression by mechanisms that are likely p53-independent.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: March 3, 2020
    Assignee: University of South Carolina
    Inventors: Ioulia Chatzistamou, Hippokratis Kiaris, Chrysovalantou Mihailidou
  • Patent number: 10570131
    Abstract: The present invention relates to heterocyclic compounds, their process of preparation, pharmaceutical compositions comprising these compounds and use thereof, optionally in combination with other antibacterial agents and/or beta-lactam compounds, for the prevention or treatment of bacterial infections. The present invention also relates to the use of these compounds as ?-lactamase inhibitors and/or as antibacterial agents.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: February 25, 2020
    Assignee: MUTABILIS
    Inventors: Julie Brias, Audrey Caravano, Sophie Chasset, Francis Chevreuil, Fabien Faivre, Benoît Ledoussal, Frédéric Le Strat, Sébastien Richard, Christophe Simon, Sophie Vomscheid
  • Patent number: 10565015
    Abstract: Provided herein is a compound of formula (I): wherein each R is independently selected from the group consisting of C1-8 alkyl, C1-8 heteroalkyl having 1-4 heteroatoms independently selected from N, O, and S, C3-6 cycloalkyl, 3-10 membered heterocycloalkyl having 1-4 heteroatoms independently selected from N, O, and S, C6-10 aryl, and 5-10 membered heteroaryl having 1-4 heteroatoms independently selected from N, O, and S; each X is independently selected from OH, PAr2, P(O)Ar2, OPAr2, C3-6 cycloalkyl, 3-10 membered heterocycloalkyl having 1-4 heteroatoms independently selected from N, O, and S or each X together form O2PNR?2; Ar is C6-10aryl; and each R? is independently selected from hydrogen and C1-8 alkyl. Also provided are methods of making and using the compound of formula (I).
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: February 18, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Pavel Nagorny, Siyuan Sun, Alonso Arguelles
  • Patent number: 10556894
    Abstract: Novel compounds useful for treating and/or preventing HCMV infections are provided.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: February 11, 2020
    Assignee: Evrys Bio, LLC
    Inventors: Stacy Remiszewski, Emre Koyuncu, Qun Sun, Lillian Chiang
  • Patent number: 10550092
    Abstract: The present invention relates to novel oxazolidinones (Formula I): or a pharmaceutically acceptable salt having ring A characterized by N-containing monocyclic, bicyclic or spirocyclic substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: February 4, 2020
    Assignee: The Global Alliance for TB Drug Development, Inc.
    Inventors: Christopher B. Cooper, Haihong Huang, Dongfeng Zhang, Nader Fotouhi, Takushi Kaneko
  • Patent number: 10544154
    Abstract: Provided herein are prodrugs of opioid receptor antagonists such as nalmefene and naltrexone, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of behavioral disorders.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: January 28, 2020
    Assignee: Nirsum Laboratories, Inc.
    Inventors: Michael W. Tusche, Nikej Shah
  • Patent number: 10538531
    Abstract: Provided herein are prodrugs of opioid receptor antagonists such as nalmefene and naltrexone, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of behavioral disorders.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: January 21, 2020
    Assignee: Nirsum Laboratories, Inc.
    Inventors: Michael W. Tusche, Nikej Shah